Caricamento...
Recent updates on CAR T clinical trials for multiple myeloma
Proteasome inhibitors, immunomodulatory agents and monoclonal antibodies have dramatically changed the natural history of multiple myeloma (MM). However, most patients eventually suffer a relapse and succumb to the disease. Chimeric antigen receptor (CAR) engineered T cells targeting B cell maturati...
Salvato in:
| Pubblicato in: | Mol Cancer |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6829852/ https://ncbi.nlm.nih.gov/pubmed/31684964 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-019-1092-1 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|